lp-a.org

Timeline 6 due · 18 done

Dates for future items are the registry's or the sponsor's guidance; where only a window is known the entry says so and carries a placeholder date inside it. Corrected the day a result is public.

Due

  1. 2027
  2. PREVAIL outcomes result (obicetrapib)

    Interim analysis Q4 2026, results expected Q1 2027

    More than 9,500 ASCVD patients; will show whether the CETP inhibitor's LDL-C, apoB and Lp(a) lowering translate into fewer events. Covered in depth on cetpinhibition.org. NewAmsterdam Pharma

    CETP inhibitionreadout
  3. EAS Congress 2027

    Upcoming

    The lipid society's annual congress; the venue where the EAS Lp(a) consensus is likely to be revisited once outcomes data exist. European Atherosclerosis Society

    congress
  4. OCEAN(a)-Outcomes result (olpasiran)

    Expected 2026 to 2027 (primary completion March 2028 on ClinicalTrials.gov)

    7,297 patients with ASCVD and Lp(a) of 200 nmol/L or more, olpasiran 75 mg every 12 weeks. Date shown is a placeholder inside Amgen's guided window. Amgen

    olpasiranphase 3readout
  5. 2029
  6. ACCLAIM-Lp(a) primary completion (lepodisiran)

    Enrolment complete; primary completion March 2029

    17,300 participants, secondary and primary prevention, dosing about every six months. Eli Lilly

    lepodisiranphase 3readout
  7. 2031
  8. MOVE-Lp(a) primary completion (muvalaplin)

    Recruiting since September 2025

    10,450 participants; the first outcomes trial of an oral Lp(a)-lowering drug. Eli Lilly

    oral inhibitionphase 3readout
  9. OCEAN(a)-PreEvent primary completion (olpasiran, primary prevention)

    Recruiting since August 2025

    11,000 people at risk of a first major cardiovascular event: the first dedicated primary-prevention outcomes trial for Lp(a). Amgen

    olpasiranphase 3primary preventionreadout

Done

  1. 2026
  2. AHA Scientific Sessions 2026

    Held

    7 to 10 November 2026, Chicago. Lp(a)HORIZON read out neutral in the opening late-breaking session (7 November, NEJM): pelacarsen lowered Lp(a) by 78 percent without reducing events. Lp(a)FRONTIERS EXPANSION (pelacarsen, 86 percent lowering in US Black/African American and Hispanic participants) followed in featured science. American Heart Association

    aha 2026congress
  3. Lp(a)HORIZON result (pelacarsen): neutral

    Reported: presented at AHA 2026 (LBS.01) and published in NEJM on 7 November 2026; hazard ratio 1.02 for the primary endpoint

    The first cardiovascular outcomes trial of an Lp(a)-lowering therapy. In 8,322 patients with established cardiovascular disease and Lp(a) of 70 mg/dL or more, monthly pelacarsen 80 mg lowered Lp(a) by about 78 percent but the primary endpoint occurred in 12.3 versus 12.1 percent over a median 4.7 years (hazard ratio 1.02, 95 percent CI 0.90 to 1.15), with no effect above 90 mg/dL. Novartis had announced a topline miss in September 2026; the full data came at AHA 2026. Novartis / Ionis

    pelacarsenphase 3readout
  4. European Commission decision on obicetrapib (Ubeslo, Evlarco)

    Approved: European Commission marketing authorisation granted in September 2026 for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg with ezetimibe 10 mg), the first approval of obicetrapib anywhere

    The first approval of a CETP inhibitor, an LDL-C-lowering drug that also lowers Lp(a) by about 37 percent. Indicated for primary hypercholesterolaemia (heterozygous familial and non-familial) and mixed dyslipidaemia, on the BROADWAY, BROOKLYN and TANDEM trials; the PREVAIL outcomes trial continues. Launch by Menarini in Europe follows. NewAmsterdam Pharma / Menarini

    CETP inhibitionregulatory
  5. ESC Congress 2026, München

    Held

    28 to 31 August 2026. Twelve Hot Line sessions; Lp(a)HORIZON was not presented here and read out at AHA 2026 instead. The first congress after the CHMP opinion on obicetrapib. European Society of Cardiology

    congressESC 2026
  6. CHMP positive opinion for obicetrapib (Ubeslo) and obicetrapib/ezetimibe (Evlarco)

    The first CETP inhibitor recommended for approval anywhere; also lowers Lp(a) by about 37 percent (Nicholls, EHJ 2026). European Medicines Agency

    CETP inhibitionregulatory
  7. Lp(a)FRONTIERS APHERESIS published: pelacarsen replaces apheresis

    The first phase 3 result for an Lp(a)-specific drug: apheresis sessions cut to 0.16 of the weekly schedule, Lp(a) down 72 percent at 52 weeks. European Heart Journal

    apheresispelacarsenphase 3
  8. 2026 ACC/AHA multisociety dyslipidemia guideline published

    Replaces the 2018 blood cholesterol guideline; scope now includes lipoprotein(a). Circulation / JACC

    guidelines
  9. 2025
  10. 2025 ESC/EAS focused update presented at ESC Congress, Madrid

    Lp(a) kept as a once-in-a-lifetime measurement and risk modifier. European Society of Cardiology

    ESC 2025guidelines
  11. ALPACA (lepodisiran phase 2) presented at ACC.25 and published in NEJM

    Time-averaged Lp(a) down 93.9 percent from day 60 to 180 after 400 mg. Eli Lilly / NEJM

    lepodisiranphase 2
  12. 2024
  13. KRAKEN and ALPACAR presented at AHA 2024

    Oral muvalaplin (up to 86 percent) and zerlasiran (more than 80 percent time-averaged) both meet their phase 2 endpoints. AHA Scientific Sessions / JAMA

    oral inhibitionphase 2zerlasiran
  14. 2022
  15. OCEAN(a)-DOSE presented at AHA 2022 and published in NEJM

    Olpasiran lowers Lp(a) by more than 95 percent at 75 mg or more every 12 weeks. Amgen / NEJM

    olpasiranphase 2
  16. EAS Lp(a) consensus statement published

    Kronenberg, Mora, Stroes and colleagues: the reference document of the current era. European Heart Journal

    consensus
  17. Lp(a)HORIZON completes enrolment (8,323 patients)

    Event-driven follow-up begins. Novartis / Ionis

    pelacarsenphase 3
  18. 2020
  19. Pelacarsen phase 2 published in NEJM: up to 80 percent Lp(a) lowering

    Tsimikas et al.; the dose selection for Lp(a)HORIZON. NEJM

    pelacarsenphase 2
  20. 2019
  21. 2019 ESC/EAS guidelines: measure Lp(a) once in every adult's lifetime

    The first major guideline with universal once-in-a-lifetime Lp(a) measurement. European Society of Cardiology / EAS

    guidelines
  22. 2013
  23. LPA identified as the genome-wide signal for aortic valve calcification (NEJM)

    Lp(a) becomes a causal factor for calcific aortic valve disease. NEJM

    aortic stenosisgenetics
  24. 2009
  25. Causality established: Clarke (NEJM) and Kamstrup (JAMA) Mendelian randomisation studies

    LPA variants raise Lp(a) and coronary risk in proportion; the field's turning point. NEJM / JAMA

    geneticshistory
  26. 1963
  27. Kåre Berg describes the Lp system

    The discovery of lipoprotein(a). Acta Pathologica et Microbiologica Scandinavica

    history